serclutamab talirine (ABBV-321) / AbbVie  >>  Phase 1
Welcome,         Profile    Billing    Logout  

1 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
serclutamab talirine (ABBV-321) / AbbVie
NCT03234712: A Study Evaluating the Safety, Pharmacokinetics, and Anti-tumor Activity of ABBV-321 in Subjects With Advanced Solid Tumors Associated With Overexpression of the Epidermal Growth Factor Receptor (EGFR)

Completed
1
62
US, RoW
ABBV-321, Serclutamab Talirine
AbbVie
Advanced Solid Tumors Cancer
04/21
04/21

Download Options